Research programme: gliadin protein therapeutics - Diamyd Medical

Drug Profile

Research programme: gliadin protein therapeutics - Diamyd Medical

Latest Information Update: 12 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer Diamyd Medical AB
  • Class Proteins
  • Mechanism of Action Gliadin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Coeliac disease; Type 1 diabetes mellitus

Most Recent Events

  • 31 Aug 2015 Diamyd Medical licenses a drug candidate from undisclosed inventors, for the treatment of type I diabetes and coeliac disease
  • 31 Aug 2015 Diamyd Medical files for patent protection for methods and formulations of gliadin, in combination with other compounds
  • 31 Aug 2015 Preclinical trials in Coeliac disease in Sweden (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top